> The lungs from patients with Covid-19 also showed distinctive vascular features, consisting of severe endothelial injury associated with the presence of intracellular virus and disrupted cell membranes. Histologic analysis of pulmonary vessels in patients with Covid-19 showed widespread thrombosis with microangiopathy. Alveolar capillary microthrombi were 9 times as prevalent in patients with Covid-19 as in patients with influenza (P<0.001). In lungs from patients with Covid-19, the amount of new vessel growth — predominantly through a mechanism of intussusceptive angiogenesis — was 2.7 times as high as that in the lungs from patients with influenza (P<0.001).

https://www.nejm.org/doi/full/10.1056/NEJMoa2015432

This is a study of the lungs of people who died. Obviously more study is needed, but it's not unreasonable to infer that people who survive COVID-19 would experience symptoms that most flu patients do not.

> there is no evidence COVID is special wrt long term complications.

Since this coronavirus is novel, and COVID-19 is a new disease, of course there are not long-term studies yet. The lack of long-term data does not provide any support for (or against) the idea that its long-term impact is similar to the flu. So we have to look at what we do know so far, which is that it is different from the flu in many ways.